Research has shown that psychedelics, such as LSD have profound anti-inflammatory properties. A new phase 1 double-blind, placebo-controlled, randomized study suggests safety of microdosing LSD and support further clinical development of LSD for the treatment and prevention of Alzheimer’s disease.